Novartis.
Swiss-American multinational pharmaceutical corporation
- Reports this week
- 9
- Active events
- 8
- Connections
- 460
What's happening
Active this week
-
Novartis acquired Avidity in a $12 billion purchase, while Trump simultaneously threatened Swiss businesses with tariffs.Some support4 reports
-
GSK and Novartis are identified as major pharmaceutical companies.Some support1 report
-
Sanofi removed Sjögren's from frexalimab and Novartis discontinued iscalimab in Sjögren's.Some support1 report
-
Anthropic and Novartis are collaborating on preclinical drug discovery programs, while the rivalry between AI firms drives market focus.Some support2 reports1 development inside
-
Novartis CEO joined Anthropic's board.Some support1 report
-
Telix agreed to acquire ITM Isotope Technologies Munich and is developing drugs that compete with Novartis.Some support2 reports
-
LVMH and Hermes contribute to the global luxury goods market, while Hoffmann-La Roche and Novartis compete in the global pharmaceutical sector.Some support1 report
-
The European Medicines Agency provided a positive opinion on a drug developed by Novartis.Some support1 report
Earlier this month
-
Titan, Novartis, and CI&T entered a licensing agreement regarding central nervous system therapeutics, competing in the small-cap technology sector.Some support1 report
-
Novartis acquired Regulus Therapeutics in April, while also reportedly weighing a potential deal with Avidity Biosciences.Well supported10 reports1 development inside
-
Novartis is offering potential support to the national health fund in Ghana, which provides equipment and support to the Komfo Anokye Teaching Hospital.Some support2 reports
-
Novartis is researching potential cures for Chagas disease in the Americas.Some support1 report
-
Novartis sought Swissmedic regulatory approval for a drug, which was co-funded by Sida and introduced first in Ghana.Some support1 report
-
Novartis and Novo Nordisk experienced simultaneous major drug program failures on September 14, 2026.Some support1 report
-
The FDA approved various advanced therapies, including oral medication from Roche, a gene-targeting drug from Biogen, and a one-time gene therapy from Novartis.Some support1 report
-
Multiple companies, including Eli Lilly, Amgen, Ionis, and Novartis, are developing advanced experimental drugs for heart disease, including those targeting Lp(a).Some support2 reports7 developments inside
-
Amgen and Novartis have developed similar drugs aimed at treating heart conditions.Some support6 reports2 developments inside
-
A rival's trial failure has challenged the shared scientific hypothesis between Amgen and Novartis.Some support1 report
-
Monte Rosa Therapeutics announced a global license agreement with Novartis and a strategic collaboration with Roche.Well supported6 reports1 development inside
-
The market is reacting to the news of Novartis' drug trial failures, specifically impacting Amgen's stock performance on the Nasdaq exchange.Some support2 reports
-
Daiichi Sankyo co-developed datopotamab deruxtecan with partners, and Jim Cramer compared AstraZeneca to Novartis.Some support2 reports
-
Avidity Biosciences, a San Diego-based company, announced a partnership with Eli Lilly and is also facing acquisition interest from Novartis.Well supported7 reports1 development inside
-
Major pharmaceutical companies, including Novartis, Roche, AstraZeneca, and Pfizer, maintain significant presences in Switzerland.Some support2 reports2 developments inside
-
Bank of America maintained its Buy rating on Novartis shares.Some support2 reports
-
Ionis Pharmaceuticals and Novartis co-developed heart drug Pelacarsen and are seeking regulatory approval for drug trials.Some support1 report
-
Dr. Iyengar gained experience during his tenure, involving companies such as Incyte, Novartis, and McKinsey & Company.Some support1 report
-
Novartis and Amgen stocks are declining, putting pressure on the Dow Jones Industrial Average due to their shared focus on cholesterol-targeting drugs.Some support1 report
-
Report covers clinical trials for Mycosis Fungoides involving Bristol-Myers Squibb, Johnson & Johnson, Merck, and Novartis.Some support3 reports1 development inside
-
Bristol-Myers Squibb paused clinical trials following clinical setbacks reported by Novartis.Some support2 reports
-
Novartis AG is subject to US federal securities laws.Some support1 report
-
Steve Rudderham held executive roles at Novartis, Syngenta, AkzoNobel, and Genpact before joining Aokah's Advisory Board.Some support1 report1 development inside
-
Amgen benefits from Novartis/Ionis Phase 3 research, Mizuho raised price targets, and the company faces a tax dispute resolution timeline.Some support4 reports
-
Iran threatens retaliation against energy infrastructure, late-stage drug trials failed, and a sweetened takeover offer was made for a former phone monopoly.Some support2 reports
-
Novartis's trial setbacks are negatively affecting market sentiment and causing a stock decline.Some support2 reports
-
Bank of America estimates the potential sales of the drug remibrutinib manufactured by Novartis.Some support4 reports
-
Novartis shares declined due to drug failure amidst geopolitical concerns regarding Iran and Oman, while Infineon benefited from an upgrade.Well supported3 reports
-
On September 7, 2026, various global events were reported, including oil price rises, tit-for-tat strikes, an election setback for Chancellor Merz, and a drug trial failure impacting a major pharmaceutical company.Some support2 reports
-
Novartis operated through a wholly owned subsidiary in India on July 1, 2026.Some support2 reports1 development inside
-
Novartis is shifting its R&D focus to India, moving operations outside of Switzerland.Some support1 report
-
Novartis' trial results are impacting Royalty Pharma's investment decisions.Some support1 report
-
Pelacarsen Phase 3 trial failure involving Ionis Pharmaceuticals and Novartis.Some support3 reports
-
Novartis announced that the Lp(a)HORIZON clinical trial failed to meet its primary endpoint on September 1, 2026.Some support3 reports
-
Anthropic has seen several high-profile appointments, including Ben Bernanke, Richard Fontaine, and a Netflix co-founder joining its trust and board.Some support1 report
-
Novartis is headquartered in Basel, Switzerland.Some support1 report1 development inside
-
Novartis is relocating activities from its Kleinbasel site and shifting production to other existing facilities across Europe.Some support2 reports
-
Novartis utilizes SAP for core inventory management.Some support1 report
-
Novartis conducted REMODEL trials for remibrutinib.Some support2 reports
-
Partnership expands Novartis's oncology pipeline.Some support2 reports2 developments inside
-
Clinical trials for a CAR-T therapy, rap-cel, have been paused due to severe adverse events.Some support1 report
-
Novartis reaches an agreement that unlocks Alteogen's technology for use in injections.Some support2 reports
One to three months ago
-
Global biotechnology company CSL, headquartered in Melbourne, focuses on specialty biotherapies and supplies raw materials for many therapies.Some support2 reports1 development inside
-
Negotiated prices are impacting market access and revenue for major pharmaceutical companies like Pfizer, UCB, Bristol-Myers Squibb, and Novartis.Some support1 report
-
Novartis and Hoffmann-La Roche sent campaign contributions to Democrats.Some support1 report
-
Major pharmaceutical companies are part of the ten largest global pharma giants as the industry seeks to weaken drug price negotiation.Some support1 report
-
Market growth is being driven by advanced therapies involving Pfizer, Novartis, and Merck.Some support1 report4 developments inside
-
Pfizer, Novartis, Merck, and Intravacc are competing in the high-cost gene therapy market, utilizing specialized manufacturing and vaccine production services.Some support1 report
-
Novartis received Health Canada approval for its therapy, Vanrafia, on August 14, 2026.Some support2 reports
-
Eli Lilly and Company and Novartis are contributing to life sciences training and growth initiatives in Indiana.Some support1 report
-
The Vanguard International High Dividend Yield ETF holds top positions in companies including Hoffmann-La Roche, HSBC, Novartis, Royal Bank of Canada, and Nestlé, with weak dollar impacting distribution.Some support1 report
-
Aly Migliori has taken on various creative projects, including commercial work for Novartis and LoveSac, and directing a campaign featuring Jordan Chiles.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Novartis this week
News at the entities that move Novartis most-
Ionis Pharmaceuticals StructuralGSK and Ionis Pharmaceuticals co-developed the bepirovirsen drug for hepatitis B.Moves Novartis
-
European Commission StructuralA European Commission summit focused on strategic cooperation, minerals, and pivoting away from the United States toward the EU.Moves Novartis
-
European Medicines Agency TransactionalBoth the FDA and the European Medicines Agency are evaluating NervGen's lead therapeutic candidate.Moves Novartis
-
Bristol-Myers Squibb OperationalBristol-Myers Squibb is developing innovative treatments and supporting Cyprus' national effort in haematology.Moves Novartis
-
Donald Trump OperationalThe Trump administration utilized the Department of Health & Human Services for an AI tool.Moves Novartis
-
Amgen OperationalAmgen, City of Hope, and the California Community Foundation are involved in a life sciences and bioscience economic summit held in Downtown Los Angeles.Moves Novartis
Connections
The 40 strongest of 460, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Regulus Structural
Novartis acquired Regulus, establishing it as a subsidiary contributing to the company's pipeline.
-
Avidity Structural
Novartis acquired Avidity Biosciences in a $12 billion buyout and continues to integrate its technology into its drug development pipeline.
-
Amgen Operational
Amgen and Novartis are direct competitors in the biopharmaceutical market, where clinical trial outcomes and market events of one significantly impact the other's stock performance and risk profile.
-
Vas Narasimhan Structural
Vas Narasimhan serves as the CEO of Novartis, managing the company through operational challenges and strategic setbacks.
-
onasemnogene abeparvovec Structural
Novartis is the company that develops, licenses, and brings the onasemnogene abeparvovec gene therapy product to market.
-
Arrowhead Pharmaceuticals Structural
Novartis licensed Arrowhead's ARO-SNCA therapy, gaining exclusive rights for development and commercialization.
-
Fiona Marshall Structural
Fiona Marshall holds the executive position of President of Biomedical Research at Novartis.
-
Monte Rosa Therapeutics Structural
Monte Rosa Therapeutics and Novartis maintain a formal, ongoing partnership through global and exclusive licensing agreements for drug development.
Show all 40 connections
-
CSL Limited Transactional
Novartis divested its influenza vaccines business unit to CSL Limited, leading to the formation of Seqirus.
-
Pfizer Transactional
Novartis acquired Pfizer's Minipress brand and trademarks in India.
-
Ionis Pharmaceuticals Structural
Novartis holds global rights from Ionis for the joint development and commercialization of advanced experimental drugs.
-
European Commission Structural
Novartis's ability to market its treatments in the EU depends on formal regulatory approval granted by the European Commission.
-
Morphosys Structural
Novartis acquired Morphosys, establishing it as a subsidiary, and the two entities maintain ongoing collaboration agreements.
-
Regulus Therapeutics Structural
Novartis acquired Regulus Therapeutics, establishing it as a subsidiary to expand its biopharmaceutical portfolio.
-
Health Canada Transactional
Health Canada granted Novartis regulatory approval for the drug Vanrafia, establishing a formal dependency.
-
Eli Lilly and Company Operational
The relationship is intense market competition, rooted in the historical divestiture of Novartis' Animal Health division to Lilly.
-
FDA Structural
FDA functions as the formal regulatory body that grants, tracks, and revokes market authorizations for Novartis' pharmaceutical products.
-
Zack Structural
Zack held clinical leadership roles at Novartis.
-
Cognizant Structural
Cognizant is contracted to implement AI-enabled integrated IT operations services for Novartis.
-
European Medicines Agency Transactional
The EMA issued a positive regulatory opinion regarding a specific drug developed by Novartis.
-
Memorial Sloan Kettering Cancer Center Structural
A functional clinical trial partnership exists between Memorial Sloan Kettering Cancer Center and Novartis, based on shared expert opinion and research goals.
-
Natco Pharma Operational
The two companies are engaged in direct market competition regarding the patent exclusivity of the drug ribociclib.
-
Hoffmann-La Roche Transactional
Novartis completed the divestiture by selling its investment stake in Hoffmann-La Roche.
-
Bristol-Myers Squibb Operational
The two companies are direct, high-stakes competitors in the advanced clinical development of treatments for myeloma.
-
Fiona Marshall Structural
Fiona Marshall holds a leadership role as president of biomedical research within the organizational structure of Novartis.
-
ReGenX Biosciences (United States) Structural
ReGenX Biosciences monetizes royalties from Novartis' Zolgensma, establishing a formal licensing and operational dependency.
-
SAP Structural
Novartis utilizes SAP for core inventory management.
-
Swissmedic Structural
Novartis relies on Swissmedic for product approval and market access in Switzerland.
-
Teva Pharmaceutical Industries Ltd. Operational
Novartis and Teva actively compete in the global pharmaceutical market, particularly in generics and biosimilars.
-
Merck Operational
The companies are direct competitors in the advanced therapies market and are frequently grouped as top holdings in sector-specific ETFs.
-
Sandoz Structural
Sandoz was historically a subsidiary of Novartis following a spin-off.
-
Alnylam Pharmaceuticals Structural
Novartis and Alnylam maintain a structural partnership where Novartis is responsible for commercializing Alnylam's therapeutic products.
-
Donald Trump Operational
Donald Trump's political actions, including administration policies and tariff threats, directly influence the operational environment and profitability of Novartis.
-
Genmab Transactional
Genmab receives royalty revenue from Novartis stemming from their collaboration on Kesimpta.
-
SEC Structural
Novartis is subject to regulatory oversight and required filings by the SEC.
-
Sarepta Therapeutics Operational
The companies are active competitors in the gene therapy space while also maintaining a formal collaboration agreement.
-
Johnson & Johnson Operational
Both Johnson & Johnson and Novartis are large pharmaceutical companies that actively compete in the oncology market.
-
Arkansas Structural
The state board of Arkansas holds formal regulatory power over Novartis regarding drug distribution and market operations.
-
Titan Transactional
The companies established a licensing agreement concerning central nervous system therapeutics.
-
Royalty Pharma Operational
Novartis' trial results influence Royalty Pharma's investment decisions.
History
Events by the month they beganSeptember 2026
38 events- Novartis acquired Avidity in a $12 billion purchase, while Trump simultaneously threatened Swiss businesses with tariffs.
- GSK and Novartis are identified as major pharmaceutical companies.
- Sanofi removed Sjögren's from frexalimab and Novartis discontinued iscalimab in Sjögren's.
- Novartis CEO joined Anthropic's board.
- Telix agreed to acquire ITM Isotope Technologies Munich and is developing drugs that compete with Novartis.
- LVMH and Hermes contribute to the global luxury goods market, while Hoffmann-La Roche and Novartis compete in the global pharmaceutical sector.
- The European Medicines Agency provided a positive opinion on a drug developed by Novartis.
- Titan, Novartis, and CI&T entered a licensing agreement regarding central nervous system therapeutics, competing in the small-cap technology sector.
- Novartis is offering potential support to the national health fund in Ghana, which provides equipment and support to the Komfo Anokye Teaching Hospital.
- Novartis is researching potential cures for Chagas disease in the Americas.
- Novartis sought Swissmedic regulatory approval for a drug, which was co-funded by Sida and introduced first in Ghana.
- Novartis and Novo Nordisk experienced simultaneous major drug program failures on September 14, 2026.
- The FDA approved various advanced therapies, including oral medication from Roche, a gene-targeting drug from Biogen, and a one-time gene therapy from Novartis.
- Amgen and Novartis have developed similar drugs aimed at treating heart conditions.
- A rival's trial failure has challenged the shared scientific hypothesis between Amgen and Novartis.
- The market is reacting to the news of Novartis' drug trial failures, specifically impacting Amgen's stock performance on the Nasdaq exchange.
- Daiichi Sankyo co-developed datopotamab deruxtecan with partners, and Jim Cramer compared AstraZeneca to Novartis.
- Bank of America maintained its Buy rating on Novartis shares.
- Ionis Pharmaceuticals and Novartis co-developed heart drug Pelacarsen and are seeking regulatory approval for drug trials.
- Dr. Iyengar gained experience during his tenure, involving companies such as Incyte, Novartis, and McKinsey & Company.
- Novartis and Amgen stocks are declining, putting pressure on the Dow Jones Industrial Average due to their shared focus on cholesterol-targeting drugs.
- Bristol-Myers Squibb paused clinical trials following clinical setbacks reported by Novartis.
- Novartis AG is subject to US federal securities laws.
- Iran threatens retaliation against energy infrastructure, late-stage drug trials failed, and a sweetened takeover offer was made for a former phone monopoly.
- Novartis's trial setbacks are negatively affecting market sentiment and causing a stock decline.
- Bank of America estimates the potential sales of the drug remibrutinib manufactured by Novartis.
- Novartis shares declined due to drug failure amidst geopolitical concerns regarding Iran and Oman, while Infineon benefited from an upgrade.
- On September 7, 2026, various global events were reported, including oil price rises, tit-for-tat strikes, an election setback for Chancellor Merz, and a drug trial failure impacting a major pharmaceutical company.
- Novartis is shifting its R&D focus to India, moving operations outside of Switzerland.
- Novartis' trial results are impacting Royalty Pharma's investment decisions.
- Pelacarsen Phase 3 trial failure involving Ionis Pharmaceuticals and Novartis.
- Novartis announced that the Lp(a)HORIZON clinical trial failed to meet its primary endpoint on September 1, 2026.
- Anthropic has seen several high-profile appointments, including Ben Bernanke, Richard Fontaine, and a Netflix co-founder joining its trust and board.
- Novartis is relocating activities from its Kleinbasel site and shifting production to other existing facilities across Europe.
- Novartis utilizes SAP for core inventory management.
- Novartis conducted REMODEL trials for remibrutinib.
- Clinical trials for a CAR-T therapy, rap-cel, have been paused due to severe adverse events.
- Novartis reaches an agreement that unlocks Alteogen's technology for use in injections.
August 2026
8 events- Negotiated prices are impacting market access and revenue for major pharmaceutical companies like Pfizer, UCB, Bristol-Myers Squibb, and Novartis.
- Novartis and Hoffmann-La Roche sent campaign contributions to Democrats.
- Major pharmaceutical companies are part of the ten largest global pharma giants as the industry seeks to weaken drug price negotiation.
- Pfizer, Novartis, Merck, and Intravacc are competing in the high-cost gene therapy market, utilizing specialized manufacturing and vaccine production services.
- Novartis received Health Canada approval for its therapy, Vanrafia, on August 14, 2026.
- Eli Lilly and Company and Novartis are contributing to life sciences training and growth initiatives in Indiana.
- The Vanguard International High Dividend Yield ETF holds top positions in companies including Hoffmann-La Roche, HSBC, Novartis, Royal Bank of Canada, and Nestlé, with weak dollar impacting distribution.
- Aly Migliori has taken on various creative projects, including commercial work for Novartis and LoveSac, and directing a campaign featuring Jordan Chiles.
July 2026
3 events- Anthropic and Novartis are collaborating on preclinical drug discovery programs, while the rivalry between AI firms drives market focus.
- Amgen benefits from Novartis/Ionis Phase 3 research, Mizuho raised price targets, and the company faces a tax dispute resolution timeline.
- Novartis operated through a wholly owned subsidiary in India on July 1, 2026.
Show 1 earlier month
June 2026
11 events- Novartis acquired Regulus Therapeutics in April, while also reportedly weighing a potential deal with Avidity Biosciences.
- Multiple companies, including Eli Lilly, Amgen, Ionis, and Novartis, are developing advanced experimental drugs for heart disease, including those targeting Lp(a).
- Monte Rosa Therapeutics announced a global license agreement with Novartis and a strategic collaboration with Roche.
- Avidity Biosciences, a San Diego-based company, announced a partnership with Eli Lilly and is also facing acquisition interest from Novartis.
- Major pharmaceutical companies, including Novartis, Roche, AstraZeneca, and Pfizer, maintain significant presences in Switzerland.
- Report covers clinical trials for Mycosis Fungoides involving Bristol-Myers Squibb, Johnson & Johnson, Merck, and Novartis.
- Steve Rudderham held executive roles at Novartis, Syngenta, AkzoNobel, and Genpact before joining Aokah's Advisory Board.
- Novartis is headquartered in Basel, Switzerland.
- Partnership expands Novartis's oncology pipeline.
- Global biotechnology company CSL, headquartered in Melbourne, focuses on specialty biotherapies and supplies raw materials for many therapies.
- Market growth is being driven by advanced therapies involving Pfizer, Novartis, and Merck.